Praktické lékárenství – 2/2019

www.praktickelekarenstvi.cz e29 AKTUÁLNÍ FARMAKOTERAPIE MÍSTO FARMAKOTERAPIE V LÉČBĚ MYASTHENIA GRAVIS PRAKTICKÉ LÉKÁRENSTVÍ 20. Piťha J. Farmakologické ovlivnění nervosvalového přenosu u myastenie gravis. Reme- dia 2004; 14: 485–494. 21. Bashuk RG, Krendell DA. Myasthenia gravis presenting as weakness after magnesium administration. Muscle and Nerve 1987; 10: 666. 22. Voháňka S, Mičánková B, Bednařík J. Long-term effect of locally administered botuli- num toxin A on neuromuscular transmission: longitudinal single-fiber EMG study. Move- ment Disorders 2007; 22: 35. 23. Itoh H, Shibata K, Nitta S. Sensitivity to vecuronium in seropositive and seronegative patients with myasthenia gravis. Anesth Analg. 2002; 95(1): 109–113. 24. Pittinger CB, Eryasa Y, Adamson R. Antibiotik inducedparalysis. AnesthAnalg 1970; 49: 487–501. 25. Parmar B, Francis PJ, Ragge NK. Statins, fibrates and ocular myasthenia. Lancet 2002; 31: 717. 26. Ozkul Y. Influence of calcium channel blocker drugs in neuromuscular transmission. Clin Neurophysiol 2007; 118(9): 2005–2008. 27. Howard JR. Adverse drug effects on neuromuscular transmission. Sem Neurol 1990, 10: 89–102. 28. Scheschonka A, Beuche W. Treatment of postherpetic pain in myasthenia gravis: exa- cerbation of weakness due to gabapentin. Pain 2003; 104: 423–424.